November 26, 2012

Microbix appoints Vaughn Embro-Pantalony as President and CEO

The Board of Directors of Microbix Biosystems Inc. is pleased to announce the appointment of Vaughn Embro-Pantalony as President and Chief Executive Officer.

Embro-Pantalony succeeds William J. Gastle who becomes Executive Chairman. Embro-Pantalony has been a member of the Microbix Board of Directors and Audit Committee since 2007.

The Company also announced that Phil Casselli, previously President of Microbix, is appointed to Senior Vice-President, Sales and Business Development. In this re-focused role, Casselli will be responsible for the top-line growth of Microbix and for the LumiSort animal reproduction venture.

William J. Gastle Executive Chairman said, "Speaking on behalf of the entire Board, we are pleased to conclude the process of selecting a new Chief Executive Officer. This succession helps position Microbix for growth-related challenges and I look forward to working with Vaughn in his new role."

Embro-Pantalony said, "My principal goal is to reward our shareholders for their on-going support. To accomplish that goal, I am focused on strengthening the Company's financial position and effectively executing our license agreement for Kinlytic with Zydus Cadila. I believe both those priorities are keys to building value for our shareholders."

Microbix Biosystems Inc. specialises in the development of the most advanced vaccine production technology and markets virology and biological products worldwide. The Company has intellectual property in large market bio-therapeutic drugs, vaccine technologies and animal reproduction technologies. It supplies customers in the US, Europe, and Asia.